These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27252515)

  • 21. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
    Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
    Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
    [No Abstract]   [Full Text] [Related]  

  • 22. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
    Saussele S; La Rosée P; Kiani A; Haverkamp W; Jentsch-Ullrich K; Stegelmann F; Rieger C; Waller CF; Franke GN; Junghanss C; Kirchmair R; Theurl M; le Coutre P
    Acta Haematol; 2024; 147(3):344-351. PubMed ID: 37848002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
    Engel NW; Constantin A; Fowlkes S; Assouline S
    J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
    [No Abstract]   [Full Text] [Related]  

  • 24. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
    Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.
    Mayer K; Gielen GH; Willinek W; Müller MC; Wolf D
    Leukemia; 2014 Apr; 28(4):976-7. PubMed ID: 24170029
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
    Boo YL; Liam CCK; Toh SG; Lim SM
    Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
    [No Abstract]   [Full Text] [Related]  

  • 29. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
    Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
    Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 32. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
    Tojo A; Kyo T; Yamamoto K; Nakamae H; Takahashi N; Kobayashi Y; Tauchi T; Okamoto S; Miyamura K; Hatake K; Iwasaki H; Matsumura I; Usui N; Naoe T; Tugnait M; Narasimhan NI; Lustgarten S; Farin H; Haluska F; Ohyashiki K
    Int J Hematol; 2017 Sep; 106(3):385-397. PubMed ID: 28444644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
    Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
    Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
    Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Boddu P; Shah AR; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jain N; Alhuraiji A; Burger J; Kornblau S; Pierce S; Dellasala S; Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2018 Jun; 59(6):1312-1322. PubMed ID: 28972430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponatinib for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
    [No Abstract]   [Full Text] [Related]  

  • 38. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
    Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ponatinib (Iclusig) for CML and Ph+ ALL.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.